tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2019-97-10-59-65tiblj-1347Research ArticleОБЗОРREVIEWНефротоксические свойства противотуберкулезных препаратовNephrotoxic characteristics of anti-tuberculosis drugsМожокинаГ. Н.MozhokinaG. N.

Можокина Галина Николаевна – доктор медицинских наук, ведущий научный сотрудник лаборатории инфекционной иммунологии, патологии и биотехнологии.

127473, Москва, ул. Достоевского, д. 4, корп. 2.

Galina N. Mozhokina – Doctor of Medical Sciences, Leading Researcher of Laboratory for Infectious Immunology, Pathology and Biotechnology. 

Build. 2, 4, Dostoevskiy St., Moscow, 127473

mojokina@mail.ruСамойловаА. Г.SamoylovaA. G.

Самойлова Анастасия Геннадьевна – доктор медицинских наук, заместитель директора по науке. ии, патологии и биотехнологии.

127473, Москва, ул. Достоевского, д. 4, корп. 2.

Anastasiya G. Samoylova – Doctor of Medical Sciences, Deputy Director for Research. 

Build. 2, 4, Dostoevskiy St., Moscow, 127473

a.samoilova.nmrc@mail.ruЗангиеваЗ. А.ZangievaZ. A.

Зангиева Залина Аланбековна – кандидат медицинских наук, врач-уролог высшей категории амбулаторно-консультативного отделения.

127473, Москва, ул. Достоевского, д. 4, корп. 2.

Zalina A. Zangieva – Candidate of Medical Sciences, Urologist of Superior Merritt of Out-Patient Consulting Department. 

Build. 2, 4, Dostoevskiy St., Moscow, 127473

zangieva.z@mail.ruФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesRussian Federation20191111201997105965Copyright © Можокина Г.Н., Самойлова А.Г., Зангиева З.А., 20192019Можокина Г.Н., Самойлова А.Г., Зангиева З.А.Mozhokina G.N., Samoylova A.G., Zangieva Z.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1347

В обзоре представлен анализ данных литературы о частоте нежелательных реакций со стороны почек при химиотерапии больных туберкулезом. Рассмотрены наиболее значимые патофизиологические механизмы развития лекарственной нефротоксичности. Показаны особенности нефротоксического действия аминогликозидов, капреомицина, рифампицина, пиразинамида, фторхинолонов, линезолида. Сделано заключение о необходимости регулярного клинико-лабораторного мониторинга функции почек для своевременного выявления нефротоксических реакций.

The review analyzes publications devoted to the frequency of renal adverse reactions during tuberculosis chemotherapy. The most significant pathophysiological mechanisms causing development of drug-induced nephrotoxicity are presented. The article describes the specific features of nephrotoxic effect of aminoglycosides, capreomycin, rifampicin, pyrazinamide, fluoroquinolones, and linezolid. The authors concluded that it was necessary to perform clinical and laboratory monitoring of kidney function for the timely detection of nephrotoxic reactions.

нежелательные побочные реакциинефротоксичностьпротивотуберкулезные препаратыadverse eventsnephrotoxicityanti-tuberculosis drugsReferencesАбдуллаев Р. Ю., Комиссарова О. Г., Чумакова Е. С., Одинец В. С. Уровень мочевой кислоты в сыворотке крови у больных впервые выявленным туберкулезом легких с множественной лекарственной устойчивостью возбудителя // Туб. и болезни легких. ‒ 2017. ‒ Т. 95, № 4. ‒ С. 31-36.Аbdullaev R.Yu., Komissarova O.G., Chumakova E.S., Odinets V.S. The level of uric acid in blood serum new patients suffering from multiple drug resistant pulmonary tuberculosis. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 4, pp. 31-36. (In Russ.)Абдусаломова М. И. Частота и характер побочных реакций от химиотерапии у больных с лекарственно-устойчивым туберкулезом легких // Молодой ученый. ‒ 2018. ‒ Т. 10, № 1 (196.1).Аbdusalomova M.I. Frequency and character of adverse reactions in the patients with drug resistant pulmonary tuberculosis. Molodoy Ucheny, 2018, vol. 10, no. 1 (196.1). (In Russ.)Бушма К. М., Спас В. В., Шапель И. А., Герасимчик П. А., Григорук А. В. К вопросу о нефротоксичности аминогликозидов // Новости хирургии. ‒ 2009. ‒ Т. 17, № 1. ‒ С. 157-162.Bushma K.M., Spas V.V., Shapel I.А., Gerasimchik P.А., Grigoruk А.V. About the nephrotoxicity of aminoglycosides. Novosti Khirurgii. 2009, vol. 17, no. 1, pp. 157-162. (In Russ.)Григорьева О. П., Савенкова Н. Д., Лозовская М. Э. Патология почек у детей с туберкулезной инфекцией // Нефрология. ‒ 2013. – Т. 17, № 6. ‒ С. 46-54.Grigorieva O.P., Savenkova N.D., Lozovskaya M.E. Kidney disorders in children with tuberculous infection. Nephrologiya, 2013, vol. 17, no. 6, pp. 46-54. (In Russ.)Зайцев А. А., Синопальников А. И. Аминогликозиды с позиций современной практики лечения инфекций дыхательных путей // Лечащий врач. ‒ 2009. ‒ № 9.Zaytsev А.А., Sinopalnikov А.I. Aminoglycosides from the position of current practice of respiratory infections treatment. Lechaschy Vrach, 2009, no. 9. (In Russ.)Иванова Д. А., Борисов С. Е. Спектр и факторы риска нежелательных побочных реакций при лечении впервые выявленных больных туберкулезом // Туб. и болезни легких. – 2017. – Т. 95, № 6. – С. 22-29.Ivanova D.А., Borisov S.E. Profile and risk factors of adverse reactions in new tuberculosis cases receiving treatment. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 6, pp. 22-29. (In Russ.)Клиническое и программное руководство по лечению туберкулеза с применением новых противотуберкулезных препаратов. ‒ Версия 4, 2018 г., 69 с.Klinicheskoe i programmnoe rukovodstvo po lecheniyu tuberkuleza s primeneniem novykh protivotuberkuleznykh preparatov. [Clinical and programmatic management for treatment of tuberculosis with new anti-tuberculosis drugs]. Version 4, 2018, 69p.Колпакова Т. А. Лекарственные нефропатии у больных туберкулезом легких с отягощенным аллергологическим анамнезом // Туб. и болезни легких. ‒ 2016. – Т. 94, № 10. ‒ С. 40-43.Kolpakova T.А. Drug-induced nephropathy in pulmonary tuberculosis patients with burdened allergic history. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 10, pp. 40-43. (In Russ.)Коновалова Н. М., Одинец В. С., Василенко Т. И., Задремайлова Т. А. Опыт применения препарата бедаквилин в лечении больных туберкулезом легких с множественной и широкой лекарственной устойчивостью возбудителя // Туб. и болезни легких. – 2017. – Т. 95, № 12. – С. 49-53.Konovalova N.M., Odinets V.S., Vasilenko T.I., Zadremaylova T.А. Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple and extensive drug resistance. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 12, pp. 49-53. (In Russ.)Лекарственные поражения почек: уч. пособие / под общ. ред. А. Б. Бакирова – Уфа: Вагант, 2016. – 71 с.Lekarstvennye porazheniya pochek: uch. posobie. [Drug-induced kidney disorders. Handbook]. A.B. Bakirova, eds., Ufa, Vagant Publ., 2016, 71 p.Лозинский Е. Ю. Клиническая нефрология. ‒ Владивосток: изд. Дальневосточного университета, 2007. ‒ 292 с.Lozinskiy E.Yu. Klinicheskaya nefrologiya. [Clinical nephrology]. Vladivostok, Izd. Dalnevostochnogo Universiteta Publ., 2007, 292 p.Скрягина Е. М., Гуревич Г. Л., Солодовникова В. В., Дюсьмикеева М. И., Сеткина С. Б., Журкин Д. М. Опыт применения новых режимов лечения туберкулеза с множественной и широкой лекарственной устойчивостью возбудителя в Республике Беларусь // Туб. и болезни легких. ‒ 2018. – Т. 96, № 8. ‒ С. 5-14.Skryagina E.M., Gurevich G.L., Solodovnikova V.V., Dyusmikeeva M.I., Setkina S.B., Zhurkin D.M. Experience of treating multiple/extensive drug resistant tuberculosis with new regimens in Belarus Republic. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 8, pp. 5-14. (In Russ.)Тихонова Л. Ю., Соколова В. В., Тарасюк И. А., Екименко А. М., Черенкова М. А., Кудлай Д. А. Опыт применения препарата бедаквилин у больных туберкулезом с множественной лекарственной устойчивостью возбудителя в Амурской области // Туб. и болезни легких. – 2018. – Т. 96, № 6. – С. 45-50.Tikhonova L.Yu., Sokolova V.V., Tarasyuk I.А., Ekimenko А.M., Cherenkova M.А., Kudlay D.А. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 45-50. (In Russ.)Токтогонова А. А. Частота и характер побочных реакций на противотуберкулезные препараты второго ряда у больных туберкулезом с множественной лекарственной устойчивостью возбудителя // Туб. и болезни легких. – 2017. – Т. 95, № 10. – С. 63-67.Toktogonova А.А. Frequency and characteristics of adverse reactions to second line anti-tuberculosis drugs in those ill with multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 10, pp. 63-67. (In Russ.)Щегерцов Д. Ю., Филинюк О. В., Буйнова Л.Н., Земляная Н. А., Кабанец Н. Н., Аллилуев А. С. Нежелательные побочные реакции при лечении больных туберкулезом с множественной лекарственной устойчивостью возбудителя // Туб. и болезни легких. – 2018 – Т. 96, № 3. – С. 35-43.Schegertsov D.Yu., Filinyuk O.V., Buynova L.N., Zemlyanaya N.А., Kabanets N.N., Аlliluev А.S. Adverse events during treatment of patients suffering from multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 3, pp. 35-43. (In Russ.)Яровой С. К., Максудов Р. Р. Медикаментозная терапия поражений почек, обусловленных нарушениями обмена пуринов // Лечащий врач. ‒ 2013. ‒ № 8.Yarovoy S.K., Maksudov R.R. Medicamentous therapy of kidney disorders caused by purine exchange disorders. Lechaschy Vrach, 2013, no. 8. (In Russ.)Afolabi O. K., Oyewo E. B. Effects of ciprofloxacin and levofloxacin administration on some oxidative stress markers in therapy // Intern. J. Biol. Veter. Agricult. Food Engineering. ‒ 2014. ‒ Vol. 8, № 1.– Р. 80-84.Afolabi O.K., Oyewo E.B. Effects of ciprofloxacin and levofloxacin administration on some oxidative stress markers in therapy. Intern. J. Biol. Veter. Agricult. Food Engineering, 2014, vol. 8, no. 1, pp. 80-84.Aminiafshar S., Alimagham M., Abbasi F., Fard-Khani S. K. Acute interstitial nephritis associated with rifampicin therapy // Saudi J. Kidney Dis. Transl. ‒ 2009. ‒ Vol. 20. ‒ Р. 1079-1080.Aminiafshar S., Alimagham M., Abbasi F., Fard-Khani S.K. Acute interstitial nephritis associated with rifampicin therapy. Saudi J. Kidney Dis. Transl., 2009, vol. 20, pp. 1079-1080.Arnold A., Cooke G. S., Kon O. M., Dedicoat M., Lipman M. et al. Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis // Antimicrob. Agents Chemother. – 2017. ‒ Vol. 61. ‒ Р. e02586-16.Arnold A., Cooke G.S., Kon O.M., Dedicoat M., Lipman M. et al. Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis. Antimicrob. Agents Chemother., 2017, vol. 61, pp. e02586-16.Awdishu L., Mehta R. L. The 6R’s of drug induced nephrotoxicity // BMC Nephrology. ‒ 2017. ‒ Vol. 18. ‒ Р. 124.Awdishu L., Mehta R.L. The 6R’s of drug induced nephrotoxicity. BMC Nephrology, 2017, vol. 18, pp. 124.Beebeab A., Seaworthc B., Patil N. Rifampicin-induced nephrotoxicity in a tuberculosis patient // J. Clin. Tuberc. Other Mycobact. Dis. ‒ 2015. ‒ Vol. 1. ‒ Р. 13-15.Beebeab A., Seaworthc B., Patil N. Rifampicin-induced nephrotoxicity in a tuberculosis patient. J. Clin. Tuberc. Other Mycobact. Dis., 2015, vol. 1, pp. 13-15.Chen D., Luo C., Tang Z., Zhou Y. et al. Delayed renal function recovery from drug-induced acute interstitial nephritis // Am. J. Med. Sci. ‒ 2012. ‒ Vol. 343, № 1. ‒ Р. 36-39.Chen D., Luo C., Tang Z., Zhou Y. et al. Delayed renal function recovery from drug-induced acute interstitial nephritis. Am. J. Med. Sci., 2012, vol. 343, no. 1, pp. 36-39.Clinical relevance // Clinical nephrotoxins: Renal injury from drugs and chemicals, 2nd ed. [Eds M. E. DeBroe, G. A. Porter, W. M. Bennett, G. A. Verpooten]. Dordrecht: Kluwer Academic, 2003. ‒ P. 3-20.Clinical relevance. Clinical nephrotoxins: Renal injury from drugs and chemicals, 2nd ed. [Eds M.E. DeBroe, G.A. Porter, W.M. Bennett, G.A. Verpooten]. Dordrecht, Kluwer Academic, 2003, pp. 3-20.Costiniuk C. T., Mccarthy A. E., Talreja H. et al. Acute renal failure and disseminated intravascular coagulation associated with rifampin in tuberculosis treatment // Intern. J. Tub. Lung Dis. ‒ 2011. ‒ Vol. 5, № 3. ‒ Р. 421.Costiniuk C.T., Mccarthy A.E., Talreja H. et al. Acute renal failure and disseminated intravascular coagulation associated with rifampin in tuberculosis treatment. Intern. J. Tub. Lung Dis., 2011, vol. 5, no. 3, pp. 421.Covic A., Goldsmith D. J. A., Segall L., Stoicescu C., Lungu S., Volovat C., Covic M. Rifampicin-induced acute renal failure: a series of 60 patients // Nephrol. Dial. Transplant. ‒ 1998. ‒ Vol. 13. ‒ Р. 924-929.Covic A., Goldsmith D.J.A., Segall L., Stoicescu C., Lungu S., Volovat C., Covic M. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol. Dial. Transplant., 1998, vol. 13, pp. 924-929.Dharnidharka V. R., Nadeau K., Cannon C. L., Harris H. W., Rosen S. Ciprofloxacin overdose:acute renal failure with prominent apoptotic changes // Am. J. Kidney Diseases. ‒ 1998. ‒ Vol. 31, № 4. ‒ Р. 710-712.Dharnidharka V.R., Nadeau K., Cannon C.L., Harris H.W., Rosen S. Ciprofloxacin overdose:acute renal failure with prominent apoptotic changes. Am. J. Kidney Diseases, 1998, vol. 31, no. 4, pp. 710-712.Feig D. I. Serum uric acid and the risk of hypertension and chronic kidney disease // Curr. Opin. Rheumatol. ‒ 2014. ‒ Vol. 26, № 2. ‒ P. 176-185.Feig D.I. Serum uric acid and the risk of hypertension and chronic kidney disease. Curr. Opin. Rheumatol., 2014, vol. 26, no. 2, pp. 176-185.Gerdan G., Nurullah A., Ucan E. S. et al. Paradoxical increase in uric acid level with allopurinol use in pyrazinamide induced hyperuricemia // Singapore Med. J. ‒ 2013. ‒ Vol. 54, № 6. ‒ Р. 125-128.Gerdan G., Nurullah A., Ucan E.S. et al. Paradoxical increase in uric acid level with allopurinol use in pyrazinamide induced hyperuricemia. Singapore Med. J., 2013, vol. 54, no. 6, pp. 125-128.Harding I., Simpson I. Levofloxacin: low potential for hepatobiliary adverse reactions // Clin. Bacter. Infect. ‒ 2001. ‒ Vol. 7. ‒ P. 164. Abstract P. 851.Harding I., Simpson I. Levofloxacin: low potential for hepatobiliary adverse reactions. Clin. Bacter. Infect., 2001, vol. 7, pp. 164. Abstract P851.Hong K. M., Eun O. K., Sang J. L. Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis // BMC Nephrology. ‒ 2013. ‒ Vol. 14. ‒ Р. 13.Hong K.M., Eun O.K., Sang J.L. Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis. BMC Nephrology, 2013, vol. 14, pp. 13.Inoue T., Ikeda N., Kurasawa T. et al. Hyperuricemia and arthralgia uring pyrazinamide treatment // Nihon Kokyuki Gakkai Zasshi. ‒ 1999. ‒ Vol. 37. ‒ Р. 115-118.Inoue T., Ikeda N., Kurasawa T. et al. Hyperuricemia and arthralgia uring pyrazinamide treatment. Nihon Naika Gakkai Zasshi, 1999, vol. 37, pp. 115-118.Jover-Saenz A., Porcel-Perez J. M., Madrona A. B., Bielsa-Martin S. Acute interstitial nephritis due to rifampicin // Enferm. Infecc. Microbiol. Clin. ‒ 2006. ‒ Vol. 24. ‒ Р. 64.Jover-Saenz A., Porcel-Perez J.M., Madrona A.B., Bielsa-Martin S. Acute interstitial nephritis due to rifampicin. Enferm. Infecc. Microbiol. Clin., 2006, vol. 24, pp. 64.Kruger B., Benck U., Singer T., Kramer B. K. Drug-induced impairment of renal function // Deutsche medizinische Wochenschrift (1946). ‒ 2012. ‒ Vol. 137, № 38. ‒ Р. 1873-1877.Kruger B., Benck U., Singer T., Kramer B. K. Drug-induced impairment of renal function. Deutsche medizinische Wochenschrift (1946), 2012, vol. 137, no. 38, pp. 1873-1877.Lipsky B. A., Baker C. A. Fluoroquinolone toxicity profiles: A review focusing on newer agents // Clin. Infect. Dis. ‒ 1999. ‒ Vol. 28, № 2. ‒ Р. 352-364.Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin. Infect. Dis., 1999, vol. 28, no. 2, pp. 352-364.Liu P., Capitano B., Stein A., El-Solh A. A. Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis // BMC Nephrology. ‒ 2017. ‒ Vol. 18. ‒ Р. 168.Liu P., Capitano B., Stein A., El-Solh A.A. Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis. BMC Nephrology, 2017, vol. 18, pp. 168.Louthrenoo W., Hongsongkiat S., Kasitanon N., Wangkaew S., Jatuworapruk K. Effect of antituberculous drugs on serum uric acid and urine uric acid excretion // J. Clin. Rheumatol. ‒ 2015. ‒ Vol. 21, № 7. ‒ Р. 346-348.Louthrenoo W., Hongsongkiat S., Kasitanon N., Wangkaew S., Jatuworapruk K. Effect of antituberculous drugs on serum uric acid and urine uric acid excretion. J. Clin. Rheumatol., 2015, vol. 21, no. 7, pp. 346-348.Matsubara R., Kibe T., Nomura T. Crystalline nephropathy caused by tosufloxacin // Pediatrics International. ‒ 2016. ‒ Vol. 58, № 11. ‒ Р. 1219-1221.Matsubara R., Kibe T., Nomura T. Crystalline nephropathy caused by tosufloxacin. Pediatrics International, 2016, vol. 58, no. 11, pp. 1219-1221.Muthukumar T., Jayakumar M., Fernando E. M., Muthusethupathi M. A. Acute renal failure due to rifampicin: a study of 25 patients // Am. J. Kidney Dis. ‒ 2002. ‒ Vol. 40. ‒ Р. 690-696.Muthukumar T., Jayakumar M., Fernando E.M., Muthusethupathi M.A. Acute renal failure due to rifampicin: a study of 25 patients. Am. J. Kidney Dis., 2002, vol. 40, pp. 690-696.Naughton C. A. Drug-induced nephrotoxicity // Am. Fam. Physician. ‒ 2008. ‒ Vol. 78, № 6. ‒ Р. 743-750.Naughton C.A. Drug-induced nephrotoxicity. Am. Fam. Physician., 2008, vol. 78, no. 6, pp. 743-750.Olayinka E. T., Ore A., Ola O. S. Influence of different doses of levofloxacin on antioxidant defense systems and markers of renal and hepatic dysfunctions in rats // Hindawi Publ. Corpor. Adv. Toxicology. – 2015. ‒ Article ID 385023. ‒ 7 p.Olayinka E.T., Ore A., Ola O.S. Influence of different doses of levofloxacin on antioxidant defense systems and markers of renal and hepatic dysfunctions in rats. Hindawi Publ. Corpor. Adv. Toxicology, 2015, Article ID 385023, 7 p.Olayinka E., Ore A., Adeyemo O. Alterations in biochemical indices and antioxidant status in rats following treatment with gatifloxacin // Brit. J. Pharmaceut. Res. ‒ 2015. ‒ Vol. 6, № 5. ‒ P. 293-305.Olayinka E., Ore A., Adeyemo O. Alterations in biochemical indices and antioxidant status in rats following treatment with gatifloxacin. Brit. J. Pharmaceut. Res., 2015, vol. 6, no. 5, pp. 293-305.Ore A., Olayinka E. T. Influence of moxifloxacin on hepatic redox status and plasma biomarkers of hepatotoxicity and nephrotoxicity in rat // Biochem. Research Internat. ‒ 2015. ‒ Article ID 192724. ‒ 8 p.Ore A., Olayinka E.T. Influence of moxifloxacin on hepatic redox status and plasma biomarkers of hepatotoxicity and nephrotoxicity in rat. Biochem. Research Internat. 2015, Article ID 192724, 8 p.Ormerod L. P., Horsfield N. Frequency and type of reactions to anti-tuberculosis drugs: observations in routine treatment // Tub. Lung Dis. ‒ 1996. ‒ Vol. 77. ‒ Р. 37-42.Ormerod L.P., Horsfield N. Frequency and type of reactions to anti-tuberculosis drugs: observations in routine treatment. Tub. Lung Dis., 1996, vol. 77, pp. 37-42.Ouppatham S., Bancha S., Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population // J. Postgrad. Med. ‒ 2008. ‒ Vol. 54, № 4. ‒ Р. 259-262.Ouppatham S., Bancha S., Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. J. Postgrad. Med., 2008, vol. 54, no. 4, pp. 259-262.Paydas S., Balal M., Karayaylali I., Seyrek N. Severe acute renal failure due to tubulointerstitial nephritis, pancreatitis, and hyperthyroidism in a patient during rifampicin therapy // Adv. Ther. ‒ 2005. ‒ Vol. 22. ‒ Р. 241-243.Paydas S., Balal M., Karayaylali I., Seyrek N. Severe acute renal failure due to tubulointerstitial nephritis, pancreatitis, and hyperthyroidism in a patient during rifampicin therapy. Adv. Ther., 2005, vol. 22, pp. 241-243.Postlethwaite A. E., Bartel A. G., Kelley W. N. Hyperuricem ia due to ethambutol // N. Engl. J. Med. ‒ 1972. ‒ Vol. 286. ‒ Р. 761-762.Postlethwaite A.E., Bartel A.G., Kelley W.N. Hyperuricem ia due to ethambutol. N. Engl. J. Med., 1972, vol. 286, pp. 761-762.Quantrill S. J., Woodhead M. A., Bell C. E., Hardy C. C., Hutchison A. J., Gokal R. Side-effects of anti-tuberculosis drug treatment in patients with chronic renal failure // Eur. Respir. J. ‒ 2002. ‒ Vol. 20. ‒ Р. 440-443.Quantrill S.J., Woodhead M.A., Bell C.E., Hardy C.C., Hutchison A.J., Gokal R. Side-effects of anti-tuberculosis drug treatment in patients with chronic renal failure. Eur. Respir. J., 2002, vol. 20, pp. 440-443.Saeed I. K., Hong K. K., Limy W., Anthony M. D., Walsh J. J. Acute renal failure secondary to tuberculosis: a diagnostic challenge case // Nephrology. ‒ 2012. ‒ Article ID 510179. ‒ 3 p.Saeed I.K., Hong K.K., Limy W., Anthony M.D., Walsh J.J. Acute renal failure secondary to tuberculosis: a diagnostic challenge case. Nephrology, 2012, Article ID 510179, 3 p.Schaberg T., Rebhan K., Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis // Eur. Respir. J. ‒ 1996. ‒ Vol. 9. ‒ Р. 2026-2030.Schaberg T., Rebhan K., Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J., 1996, vol. 9, pp. 2026-2030.Schubert C., Bates W. D., Moosa M. R. Acute tubulointerstitial nephritis related to antituberculous drug therapy // Clin. Nephrol. ‒ 2010. ‒ Vol. 73, № 6. ‒ Р. 413-419.Schubert C., Bates W.D., Moosa M.R. Acute tubulointerstitial nephritis related to antituberculous drug therapy. Clin. Nephrol., 2010, vol. 73, no. 6, pp. 413-419.Solangi G. A., Zuberi B. F., Shaikh S., Shaikh W. M. Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy // J. Coll Physicians Surg. Pak. ‒ 2004. ‒ Vol. 14, № 3. ‒ Р. 136-138.Solangi G.A., Zuberi B.F., Shaikh S., Shaikh W.M. Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy. J. Coll Physicians Surg. Pak., 2004, vol. 14, no. 3, pp. 136-138.Sousa J., Alves G., Fortuna A., Falcao A. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles // Current Drug Safety. ‒ 2014. ‒ Vol. 9, № 2. ‒ P. 89-105.Sousa J., Alves G., Fortuna A., Falcao A. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Current Drug Safety, 2014, vol. 9, no. 2, pp. 89-105.Stalker D. J., Jungbluth G. L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial // Clin. Pharmacokinet. ‒ 2003. ‒ Vol. 42, № 13. ‒ Р. 1129-1140.Stalker D.J., Jungbluth G.L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pharmacokinet., 2003, vol. 42, no. 13, pp. 1129-1140.Zhang L., Wang F., Wang X., Liu L., Wang H. The association between plasma uric acid and renal function decline in a Chinese population-based cohort // Nephrol. Dial. Transplant. ‒ 2012. ‒ Vol. 27, № 5. ‒ P. 1836-1839.Zhang L., Wang F., Wang X., Liu L., Wang H. The association between plasma uric acid and renal function decline in a Chinese population-based cohort. Nephrol. Dial. Transplant., 2012, vol. 27, no. 5, pp. 1836-1839.

The authors declare that there are no conflicts of interest present.